The Serotonin Transporter's Hidden Switch — rs25531 and SSRI Response
Important Limitation: According to 23andMe's own geneticists, rs25531 is not reliably genotyped on consumer platforms | David Hinds of 23andMe reported that "nearly everyone (99.97%) is getting called as CC, and there is no clear heterozygote cluster" and "the genotype calls for rs25531 on our platform are not meaningful". This SNP requires specialized genotyping methods. If your 23andMe data shows AA for rs25531, it is likely a technical artifact rather than your true genotype. This article is included for scientific completeness and for users who have obtained clinical genotyping.
The serotonin transporter gene SLC6A4 | encodes the protein responsible for clearing serotonin from synapses is one of the most studied genes in psychiatry. The well-known 5-HTTLPR insertion/deletion polymorphism in the gene's promoter has been linked to depression, anxiety, and antidepressant response | though results have been inconsistent across studies for decades. But rs25531, a single nucleotide A→G substitution located within the long (L) allele of 5-HTTLPR, adds a critical layer of complexity: it effectively converts an L allele to function like the short (S) allele | when G is present at rs25531, the L allele has transcriptional activity comparable to the S allele rather than high activity.
The Mechanism
The 5-HTTLPR polymorphism consists of a 44-base-pair insertion/deletion in the SLC6A4 promoter region, creating short (S, 14 repeats) and long (L, 16 repeats) variants. Early research suggested the L allele produced 2-3 times more serotonin transporter mRNA than the S allele | Lesch et al. Science, 1996. However, rs25531 revealed that not all L alleles are functionally equivalent | Hu et al. identified that an A→G substitution at rs25531 within the L allele creates a binding site for the AP-2 transcription factor.
The result is a triallelic system: LA (L allele with A at rs25531) has high transporter expression, while LG (L allele with G at rs25531) has low expression similar to the S allele | the G variant disrupts transcription factor binding, reducing promoter activity. This creates a functional hierarchy: LALA > LAS > LALG > LGLG ≈ LGS > SS in terms of serotonin transporter expression.
The Evidence
The G allele frequency varies dramatically by ancestry | European-Americans: 7.5%, African-Americans: 21%, reflecting significant population stratification. In the largest study to date of 954 African-American and 2,622 European-American subjects | Odgerel et al. Translational Psychiatry, 2013, the G allele was nearly three times more common in African-Americans, and when 5-HTTLPR and rs25531 were combined into high- and low-transcription haplotypes, African-Americans showed significantly fewer low-transcription variants overall.
The clinical significance remains controversial and inconsistent | multiple meta-analyses have produced conflicting results. Some studies suggest that individuals with LALA genotypes respond better to SSRIs | particularly in Caucasian populations, though effect sizes are modest, while others find no association between rs25531 and treatment outcome | four large studies including STAR*D analyses found no predictive value.
One study found that SSRI serum concentrations correlated with response only in LA carriers | suggesting dose-dependent effects specific to the high-expression genotype. Intriguingly, rs25531 also influences opioid analgesia | individuals with low-expression genotypes (SA/SA or SA/LG) showed significantly better pain relief from remifentanil than LALA individuals, suggesting the variant affects multiple neurotransmitter-related drug responses.
Practical Implications
The primary clinical question is whether rs25531 genotyping improves antidepressant selection beyond 5-HTTLPR alone. Current evidence suggests limited additional predictive value | CPIC does not include rs25531 in its recommendations, and multiple studies found no added specificity. The GeneSight pharmacogenomic test | a commercial panel for antidepressant selection notes that "more data is needed before the rs25531 SNP can be recommended for use in treatment selection."
However, for individuals with clinically obtained rs25531 genotyping, there are some tentative guidelines: Those with G alleles may experience more side effects from SSRIs | particularly gastrointestinal symptoms and headaches and may benefit from starting at lower doses or considering non-SSRI alternatives. Medications like mirtazapine, which has minimal serotonin transporter affinity | showed no impact or even improved response in low-expression genotypes, making them reasonable alternatives.
Interactions
Rs25531 must be interpreted together with 5-HTTLPR, as they are in tight linkage disequilibrium and the G allele is almost always found on the L allele background | rarely occurring with the S allele. The triallelic classification (LA, LG, S) provides more accurate functional prediction than the biallelic (L, S) system alone. Other SLC6A4 polymorphisms including rs2020933 and STin2 | also affect transporter expression and may compound with rs25531, though the clinical utility of multi-variant haplotypes remains uncertain.
Gene-environment interactions are also critical | the combination of low-expression genotypes and stressful life events appears to increase depression risk more than either factor alone, though this finding has been challenged by large meta-analyses. Epigenetic modifications including DNA methylation of the SLC6A4 promoter | may interact with rs25531 genotype to affect both expression and treatment response.
All Genotypes
Standard serotonin transporter expression when paired with 5-HTTLPR L allele
You have two copies of the A allele at rs25531. When combined with the long (L) variant of 5-HTTLPR, this genotype (L<sub>A</sub>) produces high levels of serotonin transporter expression. However, rs25531 only matters in the context of 5-HTTLPR — if you have the short (S) allele of 5-HTTLPR, rs25531 has minimal impact since the S allele already produces low expression. This is the most common genotype in European populations (approximately 85% have at least one A allele).
Standard serotonin transporter expression when paired with 5-HTTLPR L allele
You have two copies of the A allele at rs25531. When combined with the long (L) variant of 5-HTTLPR, this genotype (L<sub>A</sub>) produces high levels of serotonin transporter expression. However, rs25531 only matters in the context of 5-HTTLPR — if you have the short (S) allele of 5-HTTLPR, rs25531 has minimal impact since the S allele already produces low expression. This is the most common genotype in European populations (approximately 85% have at least one A allele).
One copy reduces serotonin transporter expression when on L allele
You have one A and one G allele at rs25531. The G allele reduces serotonin transporter expression when it occurs on the long (L) variant of 5-HTTLPR, creating an L<sub>G</sub> allele that functions more like the short (S) allele. Your overall serotonin transporter expression depends on your 5-HTTLPR genotype: if you have L<sub>A</sub>/L<sub>G</sub>, you have intermediate expression; if you have L<sub>G</sub>/S, you have low expression. About 21% of African-Americans and 15% of Europeans carry at least one G allele.
One copy reduces serotonin transporter expression when on L allele
You have one A and one G allele at rs25531. The G allele reduces serotonin transporter expression when it occurs on the long (L) variant of 5-HTTLPR, creating an L<sub>G</sub> allele that functions more like the short (S) allele. Your overall serotonin transporter expression depends on your 5-HTTLPR genotype: if you have L<sub>A</sub>/L<sub>G</sub>, you have intermediate expression; if you have L<sub>G</sub>/S, you have low expression. About 21% of African-Americans and 15% of Europeans carry at least one G allele.
Both copies reduce serotonin transporter when on L allele background
You have two copies of the G allele at rs25531. When combined with the long (L) variant of 5-HTTLPR, both copies produce L<sub>G</sub> alleles with low serotonin transporter expression — functionally equivalent to having two short (S) alleles. This results in reduced serotonin reuptake from synapses, leaving more extracellular serotonin available. The GG genotype is rare in European populations (1-2%) but more common in African populations (4-5%).
Both copies reduce serotonin transporter when on L allele background
You have two copies of the G allele at rs25531. When combined with the long (L) variant of 5-HTTLPR, both copies produce L<sub>G</sub> alleles with low serotonin transporter expression — functionally equivalent to having two short (S) alleles. This results in reduced serotonin reuptake from synapses, leaving more extracellular serotonin available. The GG genotype is rare in European populations (1-2%) but more common in African populations (4-5%).